JP2010503640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503640A5 JP2010503640A5 JP2009527838A JP2009527838A JP2010503640A5 JP 2010503640 A5 JP2010503640 A5 JP 2010503640A5 JP 2009527838 A JP2009527838 A JP 2009527838A JP 2009527838 A JP2009527838 A JP 2009527838A JP 2010503640 A5 JP2010503640 A5 JP 2010503640A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- molecular weight
- weight chitosan
- low molecular
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 43
- 229920001661 Chitosan Polymers 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 230000030279 gene silencing Effects 0.000 claims description 6
- 230000006196 deacetylation Effects 0.000 claims description 5
- 238000003381 deacetylation reaction Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 238000007917 intracranial administration Methods 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 210000001835 viscera Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000004876 tela submucosa Anatomy 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000006911 enzymatic reaction Methods 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 210000001508 eye Anatomy 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 210000001331 nose Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003467 cheek Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000037440 gene silencing effect Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000011239 genetic vaccination Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84472906P | 2006-09-15 | 2006-09-15 | |
| PCT/EP2007/059740 WO2008031899A2 (en) | 2006-09-15 | 2007-09-14 | Oligonucleotide non-viral delivery systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010503640A JP2010503640A (ja) | 2010-02-04 |
| JP2010503640A5 true JP2010503640A5 (enExample) | 2010-07-29 |
Family
ID=39092312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527838A Pending JP2010503640A (ja) | 2006-09-15 | 2007-09-14 | オリゴヌクレオチド非ウイルスデリバリーシステム |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7875449B2 (enExample) |
| EP (1) | EP2061516A2 (enExample) |
| JP (1) | JP2010503640A (enExample) |
| KR (1) | KR20090058562A (enExample) |
| CN (1) | CN101588821A (enExample) |
| BR (1) | BRPI0716925A2 (enExample) |
| CA (1) | CA2662560A1 (enExample) |
| IL (1) | IL197497A (enExample) |
| WO (1) | WO2008031899A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2362376T3 (es) * | 2006-07-07 | 2011-07-04 | Aarhus Universitet | Nanopartículas para la administración de ácido nucleico. |
| WO2010021720A1 (en) | 2008-08-19 | 2010-02-25 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
| WO2013059617A1 (en) * | 2011-10-21 | 2013-04-25 | Ndsu Research Foundation | Liposome compositions and methods of use |
| DK2806896T3 (en) | 2012-01-27 | 2018-03-05 | Hoffmann La Roche | Chitosan covalently bound to small molecule integrin antagonist for targeted delivery |
| KR101601035B1 (ko) | 2013-02-28 | 2016-03-08 | 주식회사 종근당 | 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물 |
| JPWO2017078054A1 (ja) | 2015-11-04 | 2018-08-30 | 株式会社ステリック再生医科学研究所 | ＲＮＡｉ分子とＮ−アセチル化キトサンとを含む複合体 |
| WO2018216792A1 (ja) * | 2017-05-26 | 2018-11-29 | 公益財団法人川崎市産業振興財団 | 血中におけるｒｎａの安定性の改善剤および投与方法 |
| CN111568856B (zh) * | 2020-06-24 | 2021-07-06 | 珠海舒桐医疗科技有限公司 | 一种阴道凝胶制剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3922260A (en) * | 1973-08-24 | 1975-11-25 | Quintin P Peniston | Process for depolymerization of chitosan |
| US6184037B1 (en) | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
| SE9904475D0 (sv) | 1999-12-08 | 1999-12-08 | Artursson | Nucleic acid delivery system |
| US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| NO317653B1 (no) | 2002-05-03 | 2004-11-29 | Stiftelsen Biopolymer | Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav. |
| NO317654B1 (no) | 2002-05-03 | 2004-11-29 | Stiftelsen Biopolymer | Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav. |
| FR2841137B1 (fr) * | 2002-06-20 | 2004-08-13 | Bioalliance Pharma | Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement |
| WO2004074314A2 (en) | 2003-02-14 | 2004-09-02 | University Of South Florida | Chistosan-microparticles for ifn gene delivery |
| WO2005113770A1 (en) | 2004-05-13 | 2005-12-01 | Institut Gustave Roussy | Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them. |
| US8399025B2 (en) * | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
| CA2628313A1 (en) | 2005-11-04 | 2007-05-31 | Bio Syntech Canada Inc. | Composition and method for efficient delivery of nucleic acids to cells using chitosan |
| US8846102B2 (en) * | 2006-03-30 | 2014-09-30 | Engene, Inc. | Non-viral compositions and methods for transfecting gut cells in vivo |
| ES2362376T3 (es) * | 2006-07-07 | 2011-07-04 | Aarhus Universitet | Nanopartículas para la administración de ácido nucleico. |
-
2007
- 2007-09-14 US US11/855,193 patent/US7875449B2/en not_active Expired - Fee Related
- 2007-09-14 BR BRPI0716925-6A2A patent/BRPI0716925A2/pt not_active IP Right Cessation
- 2007-09-14 CA CA002662560A patent/CA2662560A1/en not_active Abandoned
- 2007-09-14 KR KR1020097007646A patent/KR20090058562A/ko not_active Ceased
- 2007-09-14 JP JP2009527838A patent/JP2010503640A/ja active Pending
- 2007-09-14 WO PCT/EP2007/059740 patent/WO2008031899A2/en not_active Ceased
- 2007-09-14 EP EP07803506A patent/EP2061516A2/en not_active Withdrawn
- 2007-09-14 CN CNA2007800343442A patent/CN101588821A/zh active Pending
-
2009
- 2009-03-09 IL IL197497A patent/IL197497A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy | |
| JP2010503640A5 (enExample) | ||
| US11730826B2 (en) | Amphiphilic nanoparticles for delivery of CRISPR based therapy | |
| ES2606636T3 (es) | Composición que comprende un antagomir encapsulado | |
| JP2022166157A (ja) | 心疾患の処置のための組成物及び方法 | |
| BR112015024729B1 (pt) | Oligonucleotídeo antissenso, seu uso e composição farmacêutica | |
| US20230056466A1 (en) | Novel precursor mirna and application thereof in tumor treatment | |
| JP2007527240A5 (enExample) | ||
| JP2010532163A5 (enExample) | ||
| BR112015024764B1 (pt) | Oligonucleotídeos de tgf-beta modificados, seu uso e composições farmacêuticas que os compreendem | |
| EP2436399B1 (en) | Polymeric nano-particles for siRNA delivery using charge interaction and covalent bonding | |
| AU2019272190B2 (en) | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same | |
| CA2738070C (en) | Novel compounds for the treatment or alleviation of edema, and methods for their use | |
| Malik et al. | Advances in nanoparticle-based delivery of next generation peptide nucleic acids | |
| CN109762821B (zh) | 抑制afap1-as1表达的干扰rna及在增加乳腺癌放疗敏感性中的应用 | |
| JP7126287B2 (ja) | 核酸導入用組成物及びその利用 | |
| CN104781403A (zh) | 双调蛋白特异性-双螺旋寡核糖核苷酸,包含双螺旋寡核糖核苷酸的双螺旋寡核糖核苷酸结构,和包含以上成分的用于预防或治疗呼吸道疾病的组合物 | |
| CA2486678A1 (en) | Non-viral gene delivery system | |
| CN117660450A (zh) | 一种miRNA核酸分子、药物组合物及其在制备用于促进组织再生的药物中的应用 | |
| CN117821468A (zh) | 肺靶向可溶性PD-L1 mRNA脂质纳米颗粒及其应用 | |
| CN114807127A (zh) | 用于结缔组织生长因子的小干扰rna及其应用 | |
| CN113262307A (zh) | 用于转染的纳米复合物载体、核酸纳米药物及其制备方法和应用 | |
| TW202114711A (zh) | 新穎三甲基甘胺醯甘油組成物及其發展抗癌症藥物及ｒｎａ疫苗上的用途 | |
| CN114392361B (zh) | 一种羧甲基壳聚糖-腺病毒混合物及其应用 | |
| CN114605338B (zh) | 一种含尿嘧啶衍生物的纳米粒、核酸纳米复合物及其制备方法和用途 |